FXR activation has been reported to reduce renal overexpression of SREBP-1 and lipogenic enzymes as well as decreasing lipid accumulation in mouse models of diabetes (65) and obesity (60), thereby acting to reduce profibrotic factors. This evidence concerns the gene NR1H4 and obesity due to melanocortin 4 receptor deficiency.